Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study Intensity Therapeutics (Nasdaq: INTS) reported preliminary INVINCIBLE-4 presurgical TNBC results through March 2, 2026. Fourteen patients have been treated (7 per cohort) of a planned 61. Cohort A (INT230-6 + SOC) showed pCR in 5/7 (71.4%) vs 2/6 (33%) in SOC alone; one SOC patient remains unevaluated.A protocol amendment to Swissmedic and the Swiss Ethics Committee was submitted to resume enrollment after a September 2025 pause for skin irritations; Cohort A showed 44% fewer grade 3+ AEs versus SOC.

#INTS Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study

www.stocktitan.net/news/INTS/intensity-ther...

Intensity Therapeutics Announces Strategic Reverse Stock Split to Boost Share Value Intensity Therapeutics has announced a 1-for-25 reverse stock split aimed at increasing its share price and compliance with Nasdaq requirements, effective February 19, 2026.

Intensity Therapeutics Announces Strategic Reverse Stock Split to Boost Share Value #United_States #cancer_therapy #Intensity_Therapeutics #Shelton #INTS

Intensity Therapeutics #INTS: 2026 Growth Strategy & Clinical Milestones
prismmarketview.com/intensity-th...

Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities Intensity Therapeutics (Nasdaq: INTS) reviewed 2025 progress and outlined 2026 priorities focused on clinical development and capital discipline. Key 2025 highlights include a peer-reviewed publication reporting a 75% disease control rate and median overall survival of 11.9 months 21.3 months in a sarcoma subset), Phase 2 INVINCIBLE-4 safety observations with 50% fewer grade 3+ adverse events versus neoadjuvant chemo in early data, and initiation of a protocol amendment to revise dosing.The company raised over $20 million in 2025, extending operating runway into Q2 2027, paused Phase 3 INVINCIBLE-3 enrollment after 21 patients due to funding, and plans to seek additional capital and partner discussions in 2026.

#INTS Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities

www.stocktitan.net/news/INTS/intensity-ther...

bsky.app/profile/did:...

#ARTIS #PABRIKS
aepiot.com/advanced-sea...
#SĪRIJAS OTRĀ #REPUBLIKA
allgraph.ro/advanced-sea...
#INTS #LUBĒJS
multi-search-tag-explorer.aepiot.ro/advanced-sea...
headlines-world.com

ClearSky ClearSky - Bringing information closer to you

www.clearsky.app/globalvisibi...

better-experience.blogspot.com/2026/01/the-...

#INTS #LUBĒJS
aepiot.ro/advanced-sea...
#HORVĀTIJA 2016 #GADA #VASARAS #OLIMPISKAJĀS #SPĒLĒS
aepiot.com/advanced-sea...
#ZABORNAJAS #PILSKALNS
multi-search-tag-explorer.allgraph.ro/advanced-sea...
allgraph.ro

Book Suggestion: Black and White Sands: A bohemian life in the colonial Caribbean she turned her back on London’s high society to build a home in Calibishie, then a remote village on Dominica’s north coast.There are tales of bohemian house parties, of war and death, smugglers and servants and, above all, of stories inspired by her political life as the only woman in a colonial parliament, her love for the island’s turbulent landscapes and her curiosity about the lives and culture of its people. Media text:

Book Suggestion: Black and White Sands: A bohemian life in the colonial Caribbean: she turned her back on London’s high society to build a home in Calibishie, then a remote village on Dominica’s north coast.There are tales of… #INTs #turnedLondons #Londonssociety #societybuild #buildCalibishie

Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement Intensity Therapeutics (Nasdaq: INTS) was granted a 180-calendar-day extension by Nasdaq to regain compliance with the exchange's $1.00 minimum bid price requirement under Listing Rule 5550(a)(2).The initial 180-day period expired on December 3, 2025; the new compliance deadline is June 1, 2026. To regain compliance the company must maintain a closing bid of at least $1.00 per share for ten consecutive business days on or before June 1, 2026. The notification does not affect listing or trading, and shares will continue to trade on the Nasdaq Capital Market under the symbol INTS. The company said it will monitor the closing bid and take actions as needed to cure the deficiency before the end of the extension period.

#INTS Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

www.stocktitan.net/news/INTS/intensity-ther...

Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium Intensity Therapeutics (Nasdaq: INTS) announced two presentations at the 2025 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, TX, taking place December 9–12, 2025.Presentation 1: "Accelerating an Anthracycline-Free Future" — poster #801 (PS4-10-15) presented by Lewis Bender on Dec 11, 2025 at 5:00 PM CT. Presentation 2: INVINCIBLE-4-SAKK 66/22 Phase II early observations on intratumoral INT230-6 — poster #1589 (PS5-01-04) presented by Andreas Müller on Dec 12, 2025 at 12:00 PM CT.Both presentations describe clinical and early clinical observations for INT230-6 and potential anthracycline‑sparing combinations in breast cancer therapy.

#INTS Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium

www.stocktitan.net/news/INTS/intensity-ther...

Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Intensity Therapeutics (Nasdaq: INTS) reported Q3 2025 results and a corporate update on Nov 6, 2025. Key points: the company had $7.1 million cash as of Sept 30, 2025 and raised an additional $6.1 million in Q4 2025, extending cash runway to the end of Q1 2027.Clinical: a peer‑reviewed IT‑01 manuscript reported a 75% disease control rate (48/64) and median overall survival of 11.9 months; a metastatic sarcoma subset mOS was 21.3 months. An exploratory >40% total tumor burden dosing subgroup showed mOS 18.7 vs 3.1 months (HR 0.17; P<0.0001). No dose‑limiting toxicities reported.Program updates: INVINCIBLE‑4 dosing will be amended and enrollment expected to restart in Q1 2026; INVINCIBLE‑3 remains paused after 21 patients due to funding.

#INTS Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/INTS/intensity-ther...

🚀 Exciting times for #INTS! Trading at $0.5468, this biotech gem is riding a wave of positive clinical trial buzz. 📈 With bullish MACD signals and short-term momentum, watch for a breakout above $0.56. Targets: $0.60 & $0.65. Stop loss: $0.52. #Biotech #Stocks #FeetrAI

🚀 Intensity Therapeutics #INTS is on a rollercoaster! 📉 With volatility high and volume low, traders eye a short play if it dips below $0.52. 🎯 Target: $0.50/$0.48. RSI neutral, MACD hints bullish. Biotech risks loom, but clinical wins could surprise! Stay sharp! #FeetrAI

🚀 Exciting times for #INTS! Despite recent volatility, the MACD hints at upward momentum. Consider a LONG position if it holds above $0.52, with targets at $0.60 & $0.65. 📈 Watch for speculative moves and profit-taking. Dive in with FeetrAI's insights! #Biotech #Stocks

🚀 Exciting times for #INTS! With promising clinical trial results, this biotech gem is on a bullish run. 📈 MACD & RSI signal momentum, and the 8-day EMA is above the 20-day EMA. Targeting $0.80-$0.90 with a stop at $0.60. Stay sharp amid market shifts! #FeetrAI #Biotech

🚀 Exciting times for #INTS! Trading at $0.675, it's up from a 30-day avg of $0.315 thanks to promising cancer treatment results. With RSI near 60 and bullish MACD, watch for a break above $0.71. Short at $0.68? Target $0.65/$0.62, stop at $0.72. Stay alert! 📈 #BiotechBuzz

🚀 Exciting times for #INTS! With promising Phase 1/2 trial results for INT230-6, the stock is surging! 📈 Bullish trend confirmed as price stays above 8-day EMA. Watch out for RSI nearing overbought. Consider entry at $0.68, target $0.78 & $0.85. Stay vigilant! #BiotechBoom

🚀 Exciting times for #INTS! After a surge from $0.26 to $1.15, it's now trading around $0.73. Bullish momentum with MACD & RSI in the 60s suggests more upside! Consider entering at $0.70, targeting $0.90 & $1.10. Stop loss at $0.60. 📈 #FeetrAI #StockMarket

📢 Stocks Trending NOW: #AMZN #NFLX #ABBV #XOM #AAPL #CVX #RDDT #GETY #CTM #INTS

🚀 Exciting times for #INTS! Positive clinical trial results are fueling a rally, with strong bullish momentum and high trading volumes. Consider entering around $1.02, targeting $1.15 & $1.25. Set a stop loss at $0.90. Biotech volatility adds spice! 📈 #FeetrAI

Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock Intensity Therapeutics (Nasdaq: INTS) announced a registered direct offering of 5,000,000 shares of common stock at $0.80 per share for gross proceeds of approximately $4.0 million. The offering is expected to close on or about November 3, 2025, subject to customary closing conditions.The company expects to use net proceeds to advance clinical trials, for working capital and general corporate purposes, and expects the cash runway to extend until the end of Q1 2027. A.G.P./Alliance Global Partners is acting as sole placement agent. The offering is being made under an effective Form S-3 registration statement declared effective July 11, 2024.

#INTS Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock

www.stocktitan.net/news/INTS/intensity-ther...

Breaking News: ( NASDAQ: #INTS ) Biotech Ignites- Cancer Breakthroughs, Spider Silk Scaling, and Weight-Loss Innovation Fuel Market Momentum

Breaking News: ( NASDAQ: #INTS ) Intensity Therapeutics' Novel Cancer Therapy Shows Promise in Lancet Discovery Science Journal

Most searched small-cap stocks, Thu Oct 30th - #LAC #FUBO #SOLS #EOSE #VIVS #JBLU #RXRX #LAES #BTBT #DVLT #DNN #CVU #ONDS #CMBM #WRD #USAR #RR #INTS #GRAB #BBAI - More: crystalequityresearch.com/most-searche... - #smallcap

🚀 Exciting times for #INTS! With a surge in volume and price, driven by promising cancer trials, this biotech gem is catching eyes. RSI is high, MACD bullish—watch for volatility! Consider entry at $1.10, targeting $1.30 & $1.50. Stay sharp, it's a wild ride! #BiotechBuzz

📢 Stocks Trending NOW: #META #GOOG #RBLX #CMG #LLY #GOOGL #MA #INTS #MO #MRK

🚀 Exciting times for #INTS! Trading volume is soaring, and the stock has jumped from $0.27 to $0.87, fueled by buzz around its cancer therapies. With RSI nearing overbought and MACD hinting bullish, consider entering at $0.85. Targets: $1.00 & $1.20. Stop loss: $0.70. 📈 #BiotechBoom

📢 Join the RARC Cannabis Interest Group Meeting on Sept 25 @ 12 PM (Zoom)! Drs. Julia Chen-Sankey & Meagan Robichaud of #INTS will present: “Marketing of Hemp-Derived Cannabis Products in the U.S.”
Open to all Rutgers affiliates. 📩 rarc@bhi.rutgers.edu

First Patient Shows Complete Response: Intensity's Novel Breast Cancer Drug Shows Promise Despite Trial Pause Intensity's INT230-6 achieves pathological complete response in first TNBC patient. Trial paused for skin irritation protocol adjustments. Drug shows significant tumor necrosis pre-SOC therapy.

#INTS Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update

www.stocktitan.net/news/INTS/intensity-ther...

Integrated Neighbourhood Teams are here, and Dorset is leading the way, with joined-up, community-first care.
www.dorsetgpalliance.co.uk/resources-3

#INTs #IntegratedCare #TeamGP #Dorset #PrimaryCare